It was shown that when T cells from tumor-immunized donors were purified prior to adoptive transfer, Lyt1+ 2− (CD4+) T cells had a superior ability to cure FBL-3 erythroleukemic tumors compared to Lyt1− 2+ (CD8+) T cells (29). This evidence concerns the gene CD4 and neoplasm.